PHLDA2-mediated phosphatidic acid peroxidation triggers a distinct ferroptotic response during tumor suppression
Xin Yang,Zhe Wang,Svetlana N Samovich,Alexander A Kapralov,Andrew A Amoscato,Vladimir A Tyurin,Haider H Dar,Zhiming Li,Shoufu Duan,Ning Kon,Delin Chen,Benjamin Tycko,Zhiguo Zhang,Xuejun Jiang,Hülya Bayir,Brent R Stockwell,Valerian E Kagan,Wei Gu,Svetlana N. Samovich,Alexander A. Kapralov,Andrew A. Amoscato,Vladimir A. Tyurin,Haider H. Dar,Brent R. Stockwell,Valerian E. Kagan
DOI: https://doi.org/10.1016/j.cmet.2024.01.006
IF: 29
2024-02-01
Cell Metabolism
Abstract:Although the role of ferroptosis in killing tumor cells is well established, recent studies indicate that ferroptosis inducers also sabotage anti-tumor immunity by killing neutrophils and thus unexpectedly stimulate tumor growth, raising a serious issue about whether ferroptosis effectively suppresses tumor development in vivo. Through genome-wide CRISPR-Cas9 screenings, we discover a pleckstrin homology-like domain family A member 2 (PHLDA2)-mediated ferroptosis pathway that is neither ACSL4-dependent nor requires common ferroptosis inducers. PHLDA2-mediated ferroptosis acts through the peroxidation of phosphatidic acid (PA) upon high levels of reactive oxygen species (ROS). ROS-induced ferroptosis is critical for tumor growth in the absence of common ferroptosis inducers; strikingly, loss of PHLDA2 abrogates ROS-induced ferroptosis and promotes tumor growth but has no obvious effect in normal tissues in both immunodeficient and immunocompetent mouse tumor models. These data demonstrate that PHLDA2-mediated PA peroxidation triggers a distinct ferroptosis response critical for tumor suppression and reveal that PHLDA2-mediated ferroptosis occurs naturally in vivo without any treatment from ferroptosis inducers.
cell biology,endocrinology & metabolism